Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 62.6% in May

Aditxt, Inc. (NASDAQ:ADTX) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 91,437 shares, a decline of 62.6% from the April 30th total of 244,575 shares. Based on an average trading volume of 5,980,521 shares, the short-interest ratio is presently 0.0 days. Currently, 277.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ADTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aditxt in a report on Monday, April 20th. Wall Street Zen raised shares of Aditxt to a “sell” rating in a report on Saturday, May 23rd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Aditxt Trading Down 28.5%

Aditxt stock opened at $0.12 on Friday. The firm has a market capitalization of $3,867.60, a P/E ratio of 0.00 and a beta of 1.08. Aditxt has a 1 year low of $0.11 and a 1 year high of $53,451.08. The business has a 50-day moving average of $10.77 and a 200-day moving average of $218.09.

Aditxt (NASDAQ:ADTX) last posted its earnings results on Tuesday, March 31st. The company reported $315,563.31 earnings per share (EPS) for the quarter. Aditxt had a negative return on equity of 374.60% and a negative net margin of 360,152.50%.

Aditxt Company Profile

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.